Bladder Cancer

Thomas Powles, ASCO20: JAVELIN Bladder 100 Phase III Interim Analysis

It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]

Petros Grivas, ESMO 2019 – Advances in metastatic urothelial cancer

We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer. Questions 1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04) 2. What progress has been made in identifying biomarkers of response […]

Arlene Siefker-Radtke, ESMO 2019 – KEYNOTE-866 Phase III trial in bladder cancer

We are joined by Arlene Sietker-Radtke (The University of Texas MD Anderson Cancer Center) at ESMO 2019 to discuss her presentation on the results from the KEYNOTE-866 trial (NCT03924856). This phase III study investigates perioperative pembrolizumab or placebo in combination with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer. Questions What are the limitations […]

Enrique Grande, ESMO 2019 – Advances in first-line treatment of urothelial cancer

Enrique Grande (MD Anderson Cancer Center) discusses evolving immunotherapy combination strategies in the first line treatment of urothelial cancer at ESMO 2019. Questions 1. In which patients with urothelial cancer is immunotherapy indicated as first-line therapy? (0:04) 2. How can we improve response rates to immune checkpoint inhibitors in patients with urothelial cancer? (0:09) 3. […]

Novel Options in Metastatic and Non-surgically Curable Bladder Cancer

European Oncology & Haematology. 2018;14(2):87–95 DOI: https://doi.org/10.17925/EOH.2018.14.2.87

Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases and 165,000 deaths in 2012.1 More than 90% of bladder cancers are of urothelial cell origin and the remaining histological subtypes include either pure forms of histological variants, such as squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma, or […]

Systemic Chemotherapy for Urothelial Cancer – How to Select Systemic Therapy in Bladder Cancer

European Oncology & Haematology, 2017;13(2):134–8 DOI: https://doi.org/10.17925/EOH.2017.13.02.134

Urothelial cancer (UC) is a common malignancy both in men and women. More than 400,000 patients are diagnosed every year and approximately 150,000 die from this disease, worldwide.1 At the same time, 5-year survival rate has only been moderately increased during the last 30 years.2 UC may arise throughout the urinary tract (urinary bladder, ureter, […]

Pathways Forward in Candidate Selection for Systemic Therapy in Invasive Urothelial Cancer of the Bladder

Oncology & Hematology Review, 2016;12(1):49–50 DOI: https://doi.org/10.17925/OHR.2016.12.01.49

Urothelial carcinoma of the bladder (UCB) is a highly prevalent and lethal disease, with an estimated annual global incidence and mortality of 430,000 and 165,000, respectively.1The vast majority of mortality from UCB is due to invasive cancers (invading the muscularis propria and beyond, ≥T2) and advanced disease stages (lymph node or distant metastases, N1-3 and […]

Genomic profiling in urothelial carcinoma

Dr Jeffrey Ross, (Albany Medical College, Albany, USA) talks to ecancertv at ASCO GU 2015 about his work on the genomic profiling of bladder carcinoma, looking for genetic alterations that will give clues for future treatments.

Adjuvant chemotherapy for bladder cancer

Prof Matthew Galsky, (The Mount Sinai Hospital, New York, USA) talks to ecancertv at ASCO GU 2015 about the effectiveness of adjuvant chemotherapy in patients with bladder cancer; his findings suggest that adjuvant chemotherapy is effective.